Results for tag: PARP inhibitor Total Items Found: 9

Andres Poveda on Maintenance Olaparib in Ovarian Cancer

Type of Page:TapVideo
Edit This Item
Tags for this item:
ASCO20
PARP inhibitor

Created: 6/9/2020 10:54:32 PM

Hope Rugo on Talazoparib for Advanced Solid Tumors

Type of Page:TapVideo
Edit This Item
Tags for this item:
nccn
nccn 2020
PARP inhibitor
monotherapy
single-agent therapy

Created: 4/21/2020 6:41:13 PM

Sara Hurvitz on Talazoparib vs Chemotherapy for Breast Cancer

Type of Page:TapVideo
Edit This Item
Tags for this item:
nccn
nccn 2020
breast cancer
PARP inhibitor

Created: 4/21/2020 6:33:18 PM

Maha Hussain on Next-Generation Sequencing of Prostate Tumor Tissue

Type of Page:TapVideo
Edit This Item
Tags for this item:
gu cancers symposium
ngs
prostate cancer
genomics
targeted treatment
PARP inhibitor

Created: 2/19/2020 9:44:45 PM

Mansoor Mirza on Ovarian Cancer ESMO 2019 Top Abstracts

Type of Page:TapVideo
Edit This Item
Tags for this item:
esmo
ovarian cancer
paola-1/engot-ov25 trial
PARP inhibitor
prima/engot-ov26/gog-3012
velia/cog-3005
bevacizumab
immunotherapy
niraparib
olaparib
veliparib

Created: 9/30/2019 3:42:42 PM

Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

Type of Page:TapVideo
Edit This Item
Tags for this item:
breast cancer
TNBC
triple-negative breast cancer
PARP inhibitor
olaparib
gBRCA mutation

Created: 3/23/2018 10:23:27 PM

Linda Mileshkin, MBBS, on Solid Tumors: Early Treatment Study Results

Type of Page:TapVideo
Edit This Item
Tags for this item:
ASCO
SITC
solid tumors
anti-PD-1
BGB-A317
PARP inhibitor
BGB-290

Created: 1/28/2018 2:44:31 PM

Lisa A. Carey, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial

Type of Page:TapVideo
Edit This Item
Tags for this item:
ASCO 2017
Lisa Carey
University of North Carolina
Mark Robson
Memorial Sloan Kettering
HER2-negative
breast cancer
OlympiAD trial
germline BRCA mutation
BRCA
PARP inhibitor

Created: 6/5/2017 2:56:18 PM

Ursula A. Matulonis, MD, and Jonathan A. Ledermann, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer

Type of Page:TapVideo
Edit This Item
Tags for this item:
Dana-Farber
Cancer Research UK
ASCO 2016
Ursula Matulonis
University College London
platinum-sensitive
relapsed
Jonathan Ledermann
PARP inhibitor
serious ovarian cancer
olaparib
maintenance monotherapy
overall survival

Created: 6/8/2016 10:50:10 AM
Order By Item Count
Order Alphabetically